Effect on joint health of routine prophylaxis with Bayer’s sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-Year Spinart study

Lundin B ;
Hong W ;
Raunig D ;
Engelen S ;
Peterfy C ;
Werk ;
Manco-Johnson MJ

Lund University and Skåne University Hospital, Lund, Sweden; Bayer HealthCare Pharmaceuticals, Whippany, NJ; ICON Medical Imaging, Warrington, PA; Spire Sciences, Inc., Boca Raton, FL; Martin-Luther-Krankenhaus, Akademisches Lehrkrankenhaus der Charité - Universitätsmedizin Berlin, Berlin, Germany; Pediatrics (Hematology) and Hemophilia and Thrombosis Center, University of Colorado School of Medicine, Aurora, CO

Blood. 2014;124((21)): Abstract No. 2854